Global pegfilgrastim biosimilars market is estimated to be valued at USD 1.69 Bn in 2024 and is expected to reach USD 3.07 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031.
To learn more about this report, request sample copy
The market growth is driven by rising demand for cheaper biosimilar alternatives to the reference biologic drugs from patients struggling with healthcare costs. Biosimilars offer significant cost savings as compared to their reference biologics, and this boosts purchase of pegfilgrastim biosimilars by hospitals and cancer care centers. Rising incidence of cancer cases worldwide boosts the need for supportive care therapies such as pegfilgrastim. Moreover, the expiry of patents of major reference biologic drugs enable the commercialization of various novel biosimilars in the market. This can expand treatment access to more patients.
Increasing number of cancer cases
Rising incidence of cancer worldwide boosts demand for supportive cancer care therapies. According to WHO, cancer burden has nearly doubled since 2000 and is expected to increase in the near future. Cancer chemotherapy often results in severely low white blood cell count in patients, making them vulnerable to life-threatening infections. Pegfilgrastim is administered to patients undergoing chemotherapy to boost white blood cell count and reduce chances of infections. As more cancer patients opt for chemotherapy globally each year, there will be huge demand for pegfilgrastim to protect them from neutropenia.
Patent Expiries of Pegfilgrastim Biosimilars
Several leading brands of pegfilgrastim have lost their patent protection in the recent past, thus, allowing for manufacturing and sale of affordable biosimilar versions. Neulasta, the pioneering pegfilgrastim therapy, lost exclusivity in the U.S. in 2018. This paved way for multiple biosimilar entrants with pegfilgrastim, which are significantly lower priced than the originator brand. Healthcare systems and patients now have access to cheaper biosimilar options without compromising on quality or efficacy. This has boosted overall adoption of pegfilgrastim and volume growth prospects appear promising as physicians and patients increasingly opt for more affordable biosimilars in place of originator versions. Lower prices ensuing from patent expiry of blockbuster brands can facilitate wider global access and uptake of pegfilgrastim biosimilars.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients